Clinical Trial Search

Primary: The Percentage of Participants With a ≥ 2-grade Improvement From Baseline on the Facial Wrinkle Scale With Photonumeric Guide (FWS) According to INVESTIGATOR AND…

Primary: Response Rate — 12; 12 Participants — p=0.9489

Primary: Microbiological Cure at the TOC Visit — 59; 1 Participants

Primary: Cohorts 1 and 2: Number of Participants With Solicited Local Adverse Events (AEs) — 273; 10; 276; 15 Participants

Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) — 7; 1 Participants

Primary: Percent Reduction From Baseline in Cough Frequency (Cough Events Per Day) to the Average of Week 8 Through Week 12 — 91.7 percent reduction

Primary: Number of Participants With Worst Pain Score of Moderate to Severe on the Brief Pain Inventory — 1497; 1535 Participants

Primary: Model-Based Geometric Mean Ratio (GMR) of 24-Hour Coughs Per Hour at Week 24 — 0.47; 0.51 Ratio — p=0.713

Primary: Change From Baseline to Week 26 in Glycated Haemoglobin (HbA1c) (%) — -0.8; -1.3; -1.6; -0.7 Percentage point of HbA1C — p=0.0078

Primary: Geometric Mean Titers (GMTs) of Influenza Vaccine Antibodies at Day 1- Per Protocol Analysis Set (PPAS) — 30.8; 38.9; 50.1; 47.5 titers

Primary: Change From Baseline in the Modified UMSARS Score at Week 48 — 5.20; 4.85 units on a scale — p=0.4656

Primary: STREAM Stage 2 Primary Outcome Measure (the Proportion of Patients With a Favourable Outcome at Week 76) — 0; 133; 162; 122 Participants

Primary: Time to Sustained Recovery in Days — 11; 12 days

Primary: Geometric Mean Titer (GMT) of CHIKV-specific Neutralizing Antibodies as Determined by Microneutralization (μPRNT) Assay in Subjects Who Tested Negative for CHIKV…

Primary: Time to First Relapse of Any Mood Episode During the Double-Blind Treatment Period — NA; NA; NA; NA days — p=0.5745